cmlf-20220331
000181833112/312022Q1FALSE00018183312022-01-012022-03-310001818331us-gaap:CommonClassAMember2022-01-012022-03-310001818331us-gaap:WarrantMember2022-01-012022-03-3100018183312022-04-29xbrli:shares00018183312022-03-31iso4217:USD00018183312021-12-31iso4217:USDxbrli:shares0001818331srt:AffiliatedEntityMembercmlf:DiagnosticTestMember2022-01-012022-03-310001818331srt:AffiliatedEntityMembercmlf:DiagnosticTestMember2021-01-012021-03-310001818331cmlf:DiagnosticTestMember2022-01-012022-03-310001818331cmlf:DiagnosticTestMember2021-01-012021-03-310001818331srt:AffiliatedEntityMemberus-gaap:ProductAndServiceOtherMember2022-01-012022-03-310001818331srt:AffiliatedEntityMemberus-gaap:ProductAndServiceOtherMember2021-01-012021-03-310001818331us-gaap:ProductAndServiceOtherMember2022-01-012022-03-310001818331us-gaap:ProductAndServiceOtherMember2021-01-012021-03-3100018183312021-01-012021-03-310001818331srt:AffiliatedEntityMember2022-01-012022-03-310001818331srt:AffiliatedEntityMember2021-01-012021-03-310001818331us-gaap:CommonClassAMember2021-01-012021-03-310001818331us-gaap:PreferredStockMember2021-12-310001818331us-gaap:CommonStockMemberus-gaap:CommonClassAMember2021-12-310001818331us-gaap:AdditionalPaidInCapitalMember2021-12-310001818331us-gaap:RetainedEarningsMember2021-12-310001818331us-gaap:RetainedEarningsMember2022-01-012022-03-310001818331us-gaap:CommonStockMemberus-gaap:CommonClassAMember2022-01-012022-03-310001818331us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001818331us-gaap:PreferredStockMember2022-03-310001818331us-gaap:CommonStockMemberus-gaap:CommonClassAMember2022-03-310001818331us-gaap:AdditionalPaidInCapitalMember2022-03-310001818331us-gaap:RetainedEarningsMember2022-03-3100018183312020-12-310001818331us-gaap:CommonStockMemberus-gaap:CommonClassAMember2020-12-310001818331us-gaap:CommonStockMemberus-gaap:CommonClassBMember2020-12-310001818331us-gaap:AdditionalPaidInCapitalMember2020-12-310001818331us-gaap:RetainedEarningsMember2020-12-310001818331us-gaap:RetainedEarningsMember2021-01-012021-03-310001818331us-gaap:CommonStockMemberus-gaap:CommonClassBMember2021-01-012021-03-3100018183312021-03-310001818331us-gaap:CommonStockMemberus-gaap:CommonClassAMember2021-03-310001818331us-gaap:CommonStockMemberus-gaap:CommonClassBMember2021-03-310001818331us-gaap:AdditionalPaidInCapitalMember2021-03-310001818331us-gaap:RetainedEarningsMember2021-03-31xbrli:purecmlf:segment0001818331us-gaap:CustomerConcentrationRiskMembercmlf:PayorAMemberus-gaap:SalesRevenueNetMember2022-01-012022-03-310001818331us-gaap:CustomerConcentrationRiskMembercmlf:PayorAMemberus-gaap:SalesRevenueNetMember2021-01-012021-03-310001818331us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMembercmlf:PayorAMember2022-01-012022-03-310001818331us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMembercmlf:PayorAMember2021-01-012021-12-310001818331cmlf:PayorBMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2022-01-012022-03-310001818331cmlf:PayorBMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2021-01-012021-12-310001818331us-gaap:CustomerConcentrationRiskMembercmlf:PayorCMemberus-gaap:SalesRevenueNetMember2021-01-012021-03-310001818331us-gaap:CustomerConcentrationRiskMembercmlf:PayorDMemberus-gaap:SalesRevenueNetMember2022-01-012022-03-310001818331us-gaap:CustomerConcentrationRiskMembercmlf:PayorDMemberus-gaap:SalesRevenueNetMember2021-01-012021-03-310001818331us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMembercmlf:PayorDMember2022-01-012022-03-310001818331us-gaap:CostOfGoodsTotalMemberus-gaap:SupplierConcentrationRiskMembercmlf:SupplierAMember2022-01-012022-03-310001818331us-gaap:CostOfGoodsTotalMemberus-gaap:SupplierConcentrationRiskMembercmlf:SupplierAMember2021-01-012021-03-3100018183312020-01-012020-12-310001818331cmlf:GovernmentAssistanceCARESActProviderReliefFundMember2020-01-012020-12-310001818331cmlf:GovernmentAssistanceCARESActEmployeeRetentionCreditMember2020-01-012020-12-310001818331cmlf:GovernmentAssistanceCARESActProviderReliefFundMember2021-01-012021-03-3100018183312021-12-012021-12-310001818331srt:ScenarioForecastMember2022-12-012022-12-3100018183312021-07-220001818331cmlf:PublicWarrantsMember2021-07-220001818331cmlf:PrivatePlacementWarrantsMember2021-12-310001818331cmlf:PrivatePlacementWarrantsMember2021-07-220001818331us-gaap:CommonClassAMember2021-12-310001818331us-gaap:CommonClassAMember2021-09-04utr:D0001818331cmlf:ClassACommonStockEqualsOrExceedsThresholdOneMember2022-01-012022-03-310001818331cmlf:ClassACommonStockEqualsOrExceedsThresholdTwoMemberus-gaap:CommonClassAMember2022-03-310001818331cmlf:ClassACommonStockEqualsOrExceedsThresholdTwoMemberus-gaap:CommonClassAMember2022-01-012022-03-310001818331us-gaap:CommonClassAMember2022-03-310001818331cmlf:Sema4OpCoIncMember2022-01-012022-03-310001818331cmlf:Sema4OpCoIncMember2022-03-310001818331us-gaap:RestrictedStockUnitsRSUMembercmlf:Sema4OpCoIncMember2021-12-092021-12-090001818331us-gaap:RestrictedStockUnitsRSUMembercmlf:Sema4OpCoIncMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2021-12-090001818331us-gaap:RestrictedStockUnitsRSUMembercmlf:Sema4OpCoIncMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2021-12-090001818331us-gaap:ShareBasedCompensationAwardTrancheThreeMemberus-gaap:RestrictedStockUnitsRSUMembercmlf:Sema4OpCoIncMember2021-12-090001818331us-gaap:RestrictedStockUnitsRSUMembercmlf:Sema4OpCoIncMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2021-12-092021-12-090001818331us-gaap:RestrictedStockUnitsRSUMembercmlf:Sema4OpCoIncMember2022-01-012022-03-310001818331srt:ScenarioForecastMember2022-04-012022-06-300001818331us-gaap:AccountingStandardsUpdate201602Member2022-01-010001818331cmlf:Sema4OpCoIncMember2021-07-220001818331cmlf:Sema4OpCoIncMemberus-gaap:CommonClassAMember2021-07-222021-07-220001818331cmlf:Sema4OpCoIncMemberus-gaap:CommonClassAMember2021-07-220001818331cmlf:Sema4OpCoIncMemberus-gaap:CommonClassBMember2021-07-222021-07-220001818331cmlf:Sema4OpCoIncMember2021-02-092021-02-090001818331cmlf:Sema4OpCoIncMember2021-02-090001818331cmlf:Sema4OpCoIncMember2021-07-222021-07-220001818331cmlf:Sema4OpCoIncMembercmlf:MergerAdditionalCapitalMember2021-12-310001818331cmlf:Sema4OpCoIncMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2021-12-310001818331cmlf:DiagnosticTestThirdPartyInsuranceMember2022-01-012022-03-310001818331cmlf:DiagnosticTestThirdPartyInsuranceMember2021-01-012021-03-310001818331cmlf:DiagnosticTestInstitutionalCustomersMember2022-01-012022-03-310001818331cmlf:DiagnosticTestInstitutionalCustomersMember2021-01-012021-03-310001818331cmlf:DiagnosticTestSelfPayMember2022-01-012022-03-310001818331cmlf:DiagnosticTestSelfPayMember2021-01-012021-03-3100018183312022-04-012022-03-310001818331us-gaap:FairValueInputsLevel2Member2022-03-310001818331us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2022-03-310001818331us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2022-03-310001818331us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2022-03-310001818331us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2022-03-310001818331us-gaap:FairValueMeasurementsRecurringMember2022-03-310001818331us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-03-310001818331us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001818331us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-03-310001818331us-gaap:FairValueMeasurementsRecurringMembercmlf:PublicWarrantMember2022-03-310001818331us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Membercmlf:PublicWarrantMember2022-03-310001818331us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMembercmlf:PublicWarrantMember2022-03-310001818331us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Membercmlf:PublicWarrantMember2022-03-310001818331us-gaap:FairValueMeasurementsRecurringMembercmlf:PrivateWarrantMember2022-03-310001818331us-gaap:FairValueMeasurementsRecurringMembercmlf:PrivateWarrantMemberus-gaap:FairValueInputsLevel1Member2022-03-310001818331us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMembercmlf:PrivateWarrantMember2022-03-310001818331us-gaap:FairValueMeasurementsRecurringMembercmlf:PrivateWarrantMemberus-gaap:FairValueInputsLevel3Member2022-03-310001818331us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2021-12-310001818331us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2021-12-310001818331us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2021-12-310001818331us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2021-12-310001818331us-gaap:FairValueMeasurementsRecurringMember2021-12-310001818331us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310001818331us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001818331us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310001818331us-gaap:FairValueMeasurementsRecurringMembercmlf:PublicWarrantMember2021-12-310001818331us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Membercmlf:PublicWarrantMember2021-12-310001818331us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMembercmlf:PublicWarrantMember2021-12-310001818331us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Membercmlf:PublicWarrantMember2021-12-310001818331us-gaap:FairValueMeasurementsRecurringMembercmlf:PrivateWarrantMember2021-12-310001818331us-gaap:FairValueMeasurementsRecurringMembercmlf:PrivateWarrantMemberus-gaap:FairValueInputsLevel1Member2021-12-310001818331us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMembercmlf:PrivateWarrantMember2021-12-310001818331us-gaap:FairValueMeasurementsRecurringMembercmlf:PrivateWarrantMemberus-gaap:FairValueInputsLevel3Member2021-12-310001818331us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2022-03-310001818331us-gaap:MeasurementInputSharePriceMember2022-03-310001818331us-gaap:MeasurementInputSharePriceMember2021-12-310001818331us-gaap:MeasurementInputPriceVolatilityMember2022-03-310001818331us-gaap:MeasurementInputPriceVolatilityMember2021-12-310001818331us-gaap:MeasurementInputExpectedTermMember2022-03-31utr:Y0001818331us-gaap:MeasurementInputExpectedTermMember2021-12-310001818331us-gaap:MeasurementInputRiskFreeInterestRateMember2022-03-310001818331us-gaap:MeasurementInputRiskFreeInterestRateMember2021-12-310001818331us-gaap:FairValueInputsLevel3Member2021-12-310001818331us-gaap:FairValueInputsLevel3Member2022-01-012022-03-310001818331us-gaap:EquipmentMember2022-03-310001818331us-gaap:EquipmentMember2021-12-310001818331cmlf:EquipmentHeldUnderCapitalLeaseMember2021-12-310001818331us-gaap:LeaseholdImprovementsMember2022-03-310001818331us-gaap:LeaseholdImprovementsMember2021-12-310001818331us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2022-03-310001818331us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2021-12-310001818331us-gaap:BuildingMember2022-03-310001818331cmlf:BuildingHeldUnderCapitalLeaseMember2021-12-310001818331us-gaap:ConstructionInProgressMember2022-03-310001818331us-gaap:ConstructionInProgressMember2021-12-310001818331us-gaap:ComputerEquipmentMember2022-03-310001818331us-gaap:ComputerEquipmentMember2021-12-310001818331cmlf:FurnitureFixturesAndOtherEquipmentMember2022-03-310001818331cmlf:FurnitureFixturesAndOtherEquipmentMember2021-12-310001818331us-gaap:CostOfSalesMember2022-01-012022-03-310001818331us-gaap:CostOfSalesMember2021-01-012021-03-310001818331us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-03-310001818331us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-03-310001818331us-gaap:SellingAndMarketingExpenseMember2022-01-012022-03-310001818331us-gaap:SellingAndMarketingExpenseMember2021-01-012021-03-310001818331us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-03-310001818331us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-03-310001818331srt:AffiliatedEntityMembercmlf:RelatedPartyTSAAgreementMember2022-01-012022-03-310001818331srt:AffiliatedEntityMembercmlf:RelatedPartyTSAAgreementMember2021-01-012021-03-310001818331srt:AffiliatedEntityMembercmlf:RelatedPartyTSAAgreementMember2021-12-310001818331srt:AffiliatedEntityMembercmlf:RelatedPartyTSAAgreementMember2022-03-310001818331srt:AffiliatedEntityMembercmlf:RelatedPartyServiceAgreementsMember2022-01-012022-03-310001818331srt:AffiliatedEntityMembercmlf:RelatedPartyServiceAgreementsMember2021-01-012021-03-310001818331srt:AffiliatedEntityMembercmlf:RelatedPartyServiceAgreementsMember2022-03-310001818331srt:AffiliatedEntityMembercmlf:RelatedPartyServiceAgreementsMember2021-12-310001818331srt:AffiliatedEntityMembercmlf:PurchaseOfDiagnosticTestingKitsAndMaterialsMember2022-01-012022-03-310001818331srt:AffiliatedEntityMembercmlf:PurchaseOfDiagnosticTestingKitsAndMaterialsMemberus-gaap:CostOfSalesMember2022-01-012022-03-310001818331srt:AffiliatedEntityMembercmlf:PurchaseOfDiagnosticTestingKitsAndMaterialsMember2022-03-310001818331srt:AffiliatedEntityMembercmlf:PurchaseOfDiagnosticTestingKitsAndMaterialsMember2021-12-310001818331srt:AffiliatedEntityMemberus-gaap:CostOfSalesMember2022-01-012022-03-310001818331srt:AffiliatedEntityMemberus-gaap:CostOfSalesMember2021-01-012021-03-310001818331srt:AffiliatedEntityMembercmlf:RelatedPartyExpensesMember2022-01-012022-03-310001818331srt:AffiliatedEntityMembercmlf:RelatedPartyExpensesMember2021-01-012021-03-310001818331cmlf:SVBAgreementMemberus-gaap:RevolvingCreditFacilityMember2021-11-150001818331cmlf:SVBAgreementMemberus-gaap:LetterOfCreditMember2021-11-1500018183312021-11-150001818331cmlf:SVBAgreementMemberus-gaap:RevolvingCreditFacilityMember2021-01-012021-12-310001818331cmlf:SVBAgreementMemberus-gaap:RevolvingCreditFacilityMember2022-01-012022-03-310001818331cmlf:SVBAgreementMemberus-gaap:RevolvingCreditFacilityMember2022-03-310001818331cmlf:SVBAgreementMember2022-01-012022-03-310001818331cmlf:DECDLoanAgreementMember2017-06-300001818331cmlf:DECDLoanAgreementMember2017-06-012017-06-300001818331cmlf:DECDLoanAgreementMember2022-01-012022-03-310001818331cmlf:DECDLoanAgreementMember2021-12-310001818331cmlf:DECDLoanAgreementMember2022-03-310001818331cmlf:MasterLoanAgreementMember2020-08-012020-08-310001818331cmlf:MasterLoanAgreementMember2020-08-31cmlf:payment0001818331cmlf:MasterLoanAgreementMember2021-07-012021-07-310001818331cmlf:MasterLeaseAgreementMember2020-12-012020-12-310001818331cmlf:MasterLeaseAgreementMember2020-12-310001818331cmlf:MasterLeaseAgreementMember2021-07-012021-07-310001818331us-gaap:BuildingMember2019-04-010001818331us-gaap:BuildingMembercmlf:OneRenewalPeriodMember2019-04-012019-04-30cmlf:period0001818331us-gaap:BuildingMembercmlf:OneRenewalPeriodMember2019-04-010001818331us-gaap:BuildingMembercmlf:TwoRenewalPeriodsMember2019-04-012019-04-300001818331us-gaap:BuildingMembercmlf:TwoRenewalPeriodsMember2019-04-010001818331us-gaap:BuildingMember2019-04-012019-04-300001818331us-gaap:BuildingMember2019-04-300001818331us-gaap:BuildingMember2020-01-310001818331cmlf:DueToRelatedPartiesMember2022-03-310001818331cmlf:ShortTermLeaseLiabilitiesMember2022-03-310001818331cmlf:A2017StockIncentivePlanMemberus-gaap:EmployeeStockOptionMember2022-01-012022-03-310001818331cmlf:A2021PlanMember2021-07-220001818331cmlf:A2021PlanMember2021-07-222021-07-220001818331us-gaap:EmployeeStockMember2021-01-012021-12-310001818331us-gaap:EmployeeStockMember2022-03-310001818331cmlf:A2017StockIncentivePlanMember2021-01-012021-03-310001818331us-gaap:EmployeeStockOptionMember2022-01-012022-03-310001818331us-gaap:EmployeeStockOptionMember2021-01-012021-03-310001818331srt:MinimumMemberus-gaap:EmployeeStockOptionMember2022-01-012022-03-310001818331srt:MaximumMemberus-gaap:EmployeeStockOptionMember2022-01-012022-03-310001818331srt:MinimumMemberus-gaap:EmployeeStockOptionMember2021-01-012021-03-310001818331srt:MaximumMemberus-gaap:EmployeeStockOptionMember2021-01-012021-03-310001818331srt:MinimumMemberus-gaap:EmployeeStockOptionMember2022-03-310001818331srt:MaximumMemberus-gaap:EmployeeStockOptionMember2022-03-310001818331srt:MinimumMemberus-gaap:EmployeeStockOptionMember2021-03-310001818331srt:MaximumMemberus-gaap:EmployeeStockOptionMember2021-03-310001818331us-gaap:RestrictedStockUnitsRSUMember2022-03-310001818331us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310001818331us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2021-10-012021-12-310001818331us-gaap:RestrictedStockUnitsRSUMember2021-12-310001818331us-gaap:ShareBasedCompensationAwardTrancheOneMember2022-01-012022-03-310001818331us-gaap:ShareBasedCompensationAwardTrancheTwoMember2022-01-012022-03-310001818331us-gaap:ShareBasedCompensationAwardTrancheThreeMember2022-01-012022-03-31cmlf:employeecmlf:consultant0001818331us-gaap:StockAppreciationRightsSARSMember2022-01-012022-03-310001818331us-gaap:StockAppreciationRightsSARSMember2022-03-310001818331cmlf:EmployeeStockOptionAndRestrictedStockUnitsMember2022-01-012022-03-310001818331cmlf:EmployeeStockOptionAndRestrictedStockUnitsMember2021-01-012021-03-310001818331us-gaap:WarrantMember2022-01-012022-03-310001818331us-gaap:WarrantMember2021-01-012021-03-310001818331cmlf:EarnOutSharesMember2022-01-012022-03-310001818331cmlf:EarnOutSharesMember2021-01-012021-03-310001818331cmlf:EarnOutRestrictedStockUnitsMember2022-01-012022-03-310001818331cmlf:EarnOutRestrictedStockUnitsMember2021-01-012021-03-310001818331us-gaap:RedeemableConvertiblePreferredStockMember2022-01-012022-03-310001818331us-gaap:RedeemableConvertiblePreferredStockMember2021-01-012021-03-310001818331us-gaap:SubsequentEventMembercmlf:GeneDxLLCMember2022-04-292022-04-290001818331us-gaap:SubsequentEventMembercmlf:GeneDxLLCMember2022-04-290001818331us-gaap:SubsequentEventMemberus-gaap:PrivatePlacementMemberus-gaap:CommonClassAMember2022-04-292022-04-290001818331us-gaap:SubsequentEventMemberus-gaap:PrivatePlacementMemberus-gaap:CommonClassAMember2022-04-29

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2022
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from __________ to __________
Commission file number 001-39482
https://cdn.kscope.io/18f9b6bafa72160938768e03398070e7-cmlf-20220331_g1.jpg
Sema4 Holdings Corp.
(Exact name of registrant as specified in its charter)
Delaware
85-1966622
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
333 Ludlow Street, North Tower, 8th Floor
Stamford, Connecticut
06902
(Address of Principal Executive Offices)(Zip Code)
(800) 298-6470
Registrant's telephone number, including area code

(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Class A common stock, par value $0.0001 per shareSMFRThe Nasdaq Global Select Market
Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per shareSMFRWThe Nasdaq Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated fileroAccelerated filero
Non-accelerated filerxSmaller reporting companyx
Emerging growth companyx
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes o No x

The registrant had outstanding 377,249,186 shares of Class A common stock as of April 29, 2022.



Table of Contents
Page
Cautionary Note Regarding Forward Looking Statements



EXPLANATORY NOTE
Unless otherwise stated in this report or the context otherwise requires, references to the “Company,” “Sema4” and “we,” “us” and “our” refer to (i) Mount Sinai Genomics, Inc. d/b/a as Sema4, or Legacy Sema4, prior to the consummation of our business combination with CM Life Sciences, Inc., or CMLS, on July 22, 2021 and (ii) Sema4 Holdings Corp. and its consolidated subsidiaries following the consummation of our business combination.
In addition, on April 29, 2022, we consummated the transactions contemplated by that certain Agreement and Plan of Merger, dated as of January 14, 2022 (as amended, the “Merger Agreement”), by and among us and our wholly-owned subsidiaries, Orion Merger Sub I, Inc. (“Merger Sub I”) and Orion Merger Sub II, LLC (“Merger Sub II” and, together with Merger Sub I, “Merger Subs”), and GeneDx, Inc. (“GeneDx”), a New Jersey corporation and wholly-owned subsidiary of OPKO Health, Inc. (“OPKO”), GeneDx Holding 2, Inc., which held 100% of GeneDx (“Holdco2”), and OPKO, which provided for, among other things, the acquisition of GeneDx from OPKO. Pursuant to the terms of the Merger Agreement, we acquired GeneDx through the merger of Merger Sub I with and into Holdco2 (the “First Merger”), with Holdco2 as the surviving corporation in the First Merger. Immediately after the consummation of the First Merger, as part of the same overall transaction, Holdco2, as the surviving corporation in the First Merger, merged with and into Merger Sub II (the “Second Merger” and, together with the First Merger, the “Mergers”), with Merger Sub II as the surviving company. After giving effect to the Mergers and the other transactions contemplated by the Merger Agreement, GeneDx was converted into a Delaware limited liability company and became our wholly-owned indirect subsidiary. At the closing of the Acquisition (as defined below), we paid OPKO gross cash consideration of $150 million and issued to OPKO 80 million shares of our Class A common stock. We refer to these transactions herein as the “Acquisition.” In addition, up to $150 million is payable following the closing of the Acquisition, if certain revenue-based milestones are achieved for each of the fiscal years ending December 31, 2022 and December 31, 2023. Concurrently with the closing of the Acquisition, we also issued and sold in private placement 50,000,000 shares of our Class A common stock to certain institutional investors for aggregate gross proceeds of $200 million (the “Acquisition PIPE Investment”). Unless stated otherwise in this report, all forward-looking information contained in this report does not take into account or give any effect to the impact of the Acquisition or the Acquisition PIPE Investment.

4


CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Certain matters discussed in this report, including matters discussed under the caption “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” may constitute forward-looking statements for purposes of the Securities Act of 1933, as amended, or the Securities Act, and the Securities Exchange Act of 1934, as amended, or the Exchange Act, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from the future results, performance or achievements expressed or implied by such forward-looking statements. The words “anticipate,” “believe,” “estimate,” “may,” “expect” and similar expressions are generally intended to identify forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation, those discussed under the captions “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in this report, as well as other factors which may be identified from time to time in our other filings with the Securities and Exchange Commission, or the SEC, or in the documents where such forward-looking statements appear. All written or oral forward-looking statements attributable to us are expressly qualified in their entirety by these cautionary statements. Such forward-looking statements include, but are not limited to, statements about:
our estimates of the sufficiency of our existing capital resources combined with future anticipated cash flows to finance our operating requirements
our expected losses;
our expectations for incurring capital expenditures to expand our research and development and manufacturing capabilities;
unforeseen circumstances or other disruptions to normal business operations, including supply chain interruptions and manufacturing constraints, arising from or related to the ongoing COVID-19 pandemic;
our ability to realize the benefits expected from the Acquisition;
our expectations for generating revenue or becoming profitable on a sustained basis;
our expectations or ability to enter into service, collaboration and other partnership agreements;
our expectations or ability to build our own commercial infrastructure to scale market and sell our products;
actions or authorizations by the U.S. Food and Drug Administration, or the FDA, or other regulatory authorities;
risks related to governmental regulation and other legal obligations, including privacy, data protection, information security, consumer protection, and anti-corruption and anti-bribery;
our ability to obtain and maintain intellectual property protection for our product candidates;
our ability to compete against existing and emerging technologies;
our stock price and its volatility;
our ability to attract and retain key personnel;
third-party payor reimbursement and coverage decisions;
our reliance on third-party laboratories and service providers for our test volume in connection with our diagnostic solutions and data programs;
our expectations for future capital requirements; and
our ability to successfully implement our business strategy.
The forward-looking statements contained in this report reflect our views and assumptions only as of the date that this report is signed. Except as required by law, we assume no responsibility for updating any forward-looking statements.
We qualify all of our forward-looking statements by these cautionary statements. In addition, with respect to all of our forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
5

Table of Contents
Sema4 Holdings Corp.
Condensed Consolidated Balance Sheets
(in thousands, except share amounts)
Part I - Financial Information
Item 1. Unaudited Condensed Consolidated Financial Statements
March 31, 2022 (unaudited)December 31, 2021
Assets
Current assets:
Cash and cash equivalents$315,002 $400,569 
Accounts receivable, net37,642 26,509 
Due from related parties125 54 
Inventory, net36,318 33,456 
Prepaid expenses17,241 19,154 
Other current assets4,096 3,802 
Total current assets$410,424 $483,544 
Operating lease right-of-use assets38,417  
Property and equipment, net60,976 62,719 
Restricted cash900 900 
Other assets6,953 6,930 
Total assets$517,670 $554,093 
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable and accrued expenses$68,880 $64,801 
Due to related parties3,237 2,623 
Contract liabilities66 473 
Short-term lease liabilities5,072  
Other current liabilities23,384 33,387 
Total current liabilities$100,639 $101,284 
Long-term debt, net of current portion11,000 11,000 
Long-term lease liabilities57,478  
Other liabilities500 21,907 
Warrant liability15,177 21,555 
Earn-out contingent liability3,432 10,244 
Total liabilities$188,226 $165,990 
Commitments and contingencies (Note 10)
Stockholders’ equity:
Preferred Stock, $0.0001 par value: 1,000,000 and 0 shares authorized at March 31, 2022 and December 31, 2021, respectively; 0 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively
  
Class A common stock, $0.0001 par value, 380,000,000 shares authorized, 245,154,475 shares issued and outstanding at March 31, 2022 and $0.0001 par value: 380,000,000 shares authorized, 242,647,604 shares issued and outstanding at December 31, 2021
24 24 
Additional paid-in capital
981,757 $963,520 
Accumulated deficit
(652,337)(575,441)
Total stockholders’ equity
329,444 388,103 
Total liabilities and stockholders’ equity
$517,670 $554,093 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
6

Table of Contents
Sema4 Holdings Corp.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
(unaudited)
Three months ended March 31,
20222021 (1)
Revenue:
Diagnostic test revenue (including related party revenue of $170 and $33 for the three months ended March 31, 2022 and 2021, respectively)
$52,495 $62,760 
Other revenue (including related party revenue of $74 and $27 for the three months ended March 31, 2022 and 2021, respectively)
1,446 1,441 
Total revenue
53,941 64,201 
Cost of services (including related party expenses of $1,056 and $278 for the three months ended March 31, 2022 and 2021, respectively)
48,316 68,524 
Gross profit (loss)
5,625 (4,323)
Research and development
21,315 53,133 
Selling and marketing
29,547 35,366 
General and administrative
42,784 102,038 
Related party expenses
1,284 1,797 
Loss from operations
(89,305)(196,657)
Other income (expense), net:
Change in fair market value of warrant and earn-out contingent liabilities13,190  
Interest income
27 21 
Interest expense
(808)(723)
Other income
 5,584 
Total other income (expense), net
12,409 4,882 
Loss before income taxes
$(76,896)$(191,775)
Income tax provision
  
Net loss and comprehensive loss
$(76,896)$(191,775)
Weighted average shares outstanding of Class A common stock
244,368,743 549,778 
Basic and diluted net loss per share, Class A common stock
$(0.31)$(348.82)
(1) As previously disclosed in Note 2, “Summary of Significant Accounting Policies” to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021, certain adjustments were made to reclassify certain expenses between cost of services and operating expenses. The adjustments are reflected as disclosed.

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
7

Table of Contents
Sema4 Holdings Corp.
Condensed Consolidated Statement of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)
(in thousands, except share amounts)
(unaudited)

Three months ended March 31, 2022
Preferred StockClass A Common StockAdditional paid-in capitalAccumulated deficitTotal stockholders’ equity
SharesPar valueSharesPar value
Balances at December 31, 2021242,647,604$24 $963,520 $(575,441)$388,103 
Net loss— — — — — (76,896)(76,896)
Stock option exercises— — 2,108,502 — 678 — 678 
Stock based compensation expense— — — — 17,559 — 17,559 
Vested restricted stock units converted to common stock— — 398,369 
Balances at March 31, 2022
$ 245,154,475$24 $981,757 $(652,337)$329,444 

                                                    Three months ended March 31, 2021 (1)
Redeemable Convertible Preferred StockClass A Common StockClass B Common StockAdditional paid-in capitalAccumulated deficit (1)Total stockholders’ (deficit)
SharesAmountSharesPar valueSharesPar value
Balances at December 31, 2020171,535,213$334,439 124$ 130,557$ $ $(330,051)$(330,051)
Net loss— — — — — — — (191,775)(191,775)
Common stock class B issued pursuant to stock options— — — — 618,204 — — —  
Balances at March 31, 2021
171,535,213$334,439 124$ 748,761$ $ (521,826)(521,826)
(1) As previously disclosed in Note 2, “Summary of Significant Accounting Policies” to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021, certain adjustments were made which impacted previously reported net loss for the first quarter of 2021 and the adjusted net loss is reflected as disclosed.

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
8

Table of Contents
Sema4 Holdings Corp.
Condensed Consolidated Statements of Cash Flows
(in thousands)
(unaudited)
Three months ended March 31,
20222021 (1)
Operating activities
Net loss
$(76,896)$(191,775)

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense
5,803 4,902 
Stock-based compensation expense
17,559 164,962 
Change in fair value of warrant and earn-out contingent liabilities
(13,190) 
Provision for excess and obsolete inventory
43 1,821 
Non-cash lease expense
167 191 
Amortization of deferred debt issuance costs128  
Change in operating assets and liabilities:
Accounts receivable
(11,132)(1,296)
Inventory
(2,904)(9,828)
Prepaid expenses and other current assets
1,596 (6,327)
Due to/from related parties
543 (688)
Other assets
(151) 
Accounts payable and accrued expenses
3,932 3,951 
Contract liabilities
(408)1,027 
Other current liabilities
(6,584)(9,148)
Net cash used in operating activities
(81,494)(42,208)

Investing activities
Purchases of property and equipment
(1,378)(2,075)
Development of internal-use software assets
(2,535)(2,919)
Net cash used in investing activities
(3,913)(4,994)

Financing activities
Payment of deferred transaction costs     (1,254)
Finance lease principal payments(862)(1,052)
Long-term debt principal payments (394)
Exercise of stock options702 422 
Net cash used in financing activities
(160)(2,278)

Net decrease in cash, cash equivalents and restricted cash
(85,567)(49,480)
Cash, cash equivalents and restricted cash, at beginning of period
401,469 118,960 
Cash, cash equivalents and restricted cash, at end of period
$315,902 $69,480 

Supplemental disclosures of cash flow information
Cash paid for interest
$607 $723 
Cash paid for taxes
$168 $ 
Purchases of property and equipment in accounts payable and accrued expenses
$1,325 $1,164 
Software development costs in accounts payable and accrued expenses
$717 $1,570 
Unpaid deferred transaction costs included in accounts payable and accrued expenses$227 $4,228 
(1) As previously disclosed in Note 2, “Summary of Significant Accounting Policies” to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021, certain adjustments were made to certain current asset and liability accounts previously reported in the condensed balance sheets as of March 31, 2021. The adjustments are reflected accordingly as disclosed.
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
9

Table of Contents
Sema4 Holdings Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
1. Organization and Description of Business
Sema4 Holdings Corp. (“Sema4 Holdings”) through its subsidiary Sema4 OpCo, Inc.,, formerly Mount Sinai Genomics Inc., a Delaware corporation (“Legacy Sema4”), as discussed further below, provides genomics-related diagnostic and information services and pursues genomics medical research. Legacy Sema4 utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process DNA-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. Legacy Sema4 provides a variety of genetic diagnostic tests and information with a focus on reproductive health, including pediatric, oncology and other conditions. Legacy Sema4 primarily serves healthcare professionals who work with their patients and bills third-party payors across the United States, with a substantial portion of its diagnostic testing volume occurring in New York, California, Florida, Connecticut and New Jersey.
On July 22, 2021 (the “Closing Date”), CM Life Sciences, Inc. (“CMLS”) completed the acquisition of Legacy Sema4, pursuant to that certain Agreement and Plan of Merger (as amended, the “Prior Merger Agreement”), dated February 9, 2021. On the Closing Date, S-IV Sub, Inc. (“Prior Merger Sub”) merged with and into the Legacy Sema4, with Legacy Sema4 surviving the merger as a wholly-owned subsidiary of CMLS (the “Prior Merger” and, together with the other transactions contemplated by the Prior Merger Agreement, the “Business Combination”). In connection with the consummation of the Business Combination, CMLS changed its name to “Sema4 Holdings Corp.” and Legacy Sema4 changed its name to “Sema4 OpCo, Inc.” All equity securities of Legacy Sema4 were converted into the right to receive the applicable portion of the merger consideration.
The Prior Merger was accounted for as a reverse recapitalization with Legacy Sema4 as the accounting acquirer and CMLS as the acquired company for accounting purposes. The shares and net loss per common share, prior to the Prior Merger, have been retroactively restated as shares reflecting the exchange ratio established in the Prior Merger (1 share of Legacy Sema4 Class A common stock for 123.8339 shares of Sema4 Holdings Class A common stock (the “Class A common stock”)) (the “Conversion Ratio”).
Prior to the Prior Merger, shares of CMLS Class A common stock, CMLS’s public warrants, and CMLS’s public units were traded on the Nasdaq Capital Market under the ticker symbols “CMLF”, “CMFLW”, and “CMLFU” respectively. On July 23, 2021, shares of Sema4 Holdings Class A common stock and Sema4 Holdings’ public warrants began trading on the Nasdaq Global Select Market (the “Nasdaq”) under the ticker symbols “SMFR” and “SMFRW,” respectively. See Note 3, “Business Combination,” for additional details.
Unless otherwise stated herein or unless the context otherwise requires, references in these notes to the “Company,” or “Sema4” refer to (i) Legacy Sema4 prior to the consummation of the Business Combination; and (ii) Sema4 Holdings and its subsidiaries following the consummation of the Business Combination.
2. Summary of Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the accounting disclosure rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. As such, the accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto as of and for the years ended December 31, 2021, 2020 and 2019 included in the Company’s Annual Report on Form 10-K for the year ended December 21, 2021 filed on March 14, 2022 (the “Annual Report”).
The accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments that are necessary to state fairly the results for the interim periods presented. Interim results are not necessarily indicative of the results of operations or cash flows for a full year or any subsequent interim period.
The Company’s historical financial information includes costs of certain services historically provided by Icahn School of Medicine at Mount Sinai (“ISMMS”) pursuant to the Transition Services Agreement ("TSA") and service agreements.
10

Table of Contents
Sema4 Holdings Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
As discussed in the Company’s Annual Report, the Company identified the misclassification of certain expenses and out of period adjustments generally related to the recognition of cost of services. The impact of these adjustments were disclosed in the Company’s Annual Report and are reflected in the condensed consolidated statements of operations and comprehensive loss, condensed consolidated statement of redeemable convertible preferred stock and stockholders’ equity (deficit) and condensed consolidated statements of cash flows for the period ended March 31, 2021.
Although the Company has incurred recurring losses in each year since inception, the Company expects its cash and cash equivalents will be sufficient to fund operations for at least the next twelve months from the date of filing of this Form 10-Q.
Segment Information
The Company operates and manages its business as one reportable operating segment based on how the Chief Executive Officer, who is the Company’s chief operating decision maker (“CODM”), assesses performance and allocates resources across the business.
Use of Estimates
The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the unaudited condensed consolidated financial statements as well as the reported amounts of revenues and expenses during the periods presented. The Company bases these estimates on current facts, historical and anticipated results, trends and various other assumptions that it believes are reasonable in the circumstances, including assumptions as to future events. These estimates include, but are not limited to, the transaction price for certain contracts with customers, the capitalization of software costs and the valuation of stock-based awards, inventory, earn-out contingent liability and earn-out Restricted Stock Units (“RSUs”). Actual results could differ materially from those estimates, judgments and assumptions.
Concentration of Credit Risk and Other Risks and Uncertainties
Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable.
The Company’s cash and cash equivalents are deposited with high-quality financial institutions. The Company has balances in financial institutions that exceed federal depository insurance limits. Management believes these financial institutions are financially sound and, accordingly, that minimal credit risk exists. The Company has not experienced any losses on its deposits of cash and cash equivalents.
The Company assesses both the self-pay patient and, if applicable, the third-party payor that reimburses the Company on the patient’s behalf when evaluating the concentration of credit risk. Significant customers and payors are those that represent more than 10% of the Company’s total revenues for the period or accounts receivable balance at each respective balance sheet date. The significant concentrations of accounts receivable as of March 31, 2022 and December 31, 2021 were primarily from large managed care insurance companies and a reference laboratory. There was no individual patient that accounted for 10% or more of the Company’s revenue or accounts receivable for any of the periods presented. The Company does not require collateral as a means to mitigate customer credit risk.
For each significant payor, revenue as a percentage of total revenues and accounts receivable as a percentage of total accounts receivable are as follows:
11

Table of Contents
Sema4 Holdings Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
RevenueAccounts Receivable
Three months ended March 31,
As of
March 31,
As of
December 31,
2022202120222021
Payor A24%14%26%15%
Payor B
**19%15%
Payor C
*12%**
Payor D
10%12%11%*
*less than 10%
The Company is subject to a concentration of risk from a limited number of suppliers for certain reagents and laboratory supplies. One supplier accounted for approximately 13% and 11% for the three months ended March 31, 2022 and 2021, respectively. This risk is managed by maintaining a target quantity of surplus stock.
Impact of COVID-19

Beginning in April 2020, the Company’s diagnostic test volumes decreased significantly as compared to the prior year as a result of the initial outbreak of the COVID-19 pandemic and the related limitations and priorities across the healthcare system. In response, beginning in May 2020, the Company entered into several service agreements with state governments and healthcare institutions to provide testing for the presence of COVID-19 variants. While test volumes have since improved, the Company continues to experience changes in the mix of tests due to the impact of the COVID-19 pandemic. COVID-19 could continue to have a material impact on the Company’s results of operations, cash flows and financial condition for the foreseeable future.
In March 2020, the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”) was signed into law which was a stimulus bill that, among other things, provided assistance to qualifying businesses and individuals and included funding for the healthcare system. During 2020, as part of the stimulus provided by the CARES Act, the Company received $5.4 million, comprised of $2.6 million received under the Provider Relief Fund (“PRF”) distribution and $2.8 million received under the Employee Retention Credit (“ERC”) distribution which was recorded in other current liabilities and reflected in this balance as of March 31, 2022 and December 31, 2021.
During the three months ended March 31, 2021, the Company received an additional $5.6 million under the PRF distribution, which was recognized in other income in the condensed consolidated statements of operations and comprehensive loss.
Additionally, under the CARES Act, the Company deferred payment of U.S. social security taxes in 2020. As a result, $3.8 million of employer payroll tax payments were initially deferred as of December 31, 2020 with $1.9 million paid in December 2021 and the remaining $1.9 million payment will be made in December 2022. As of March 31, 2022, the remaining payable is recorded in other current liabilities.
Following the Company’s announcement that it would discontinue COVID-19 testing services by March 31, 2022, the Company no longer provides COVID-19 testing services. During the three months ended March 31, 2022, the Company wrote off an accounts receivable balance of $0.5 million related to COVID-19 testing services.
Cash, Cash Equivalents and Restricted Cash
The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist of amounts invested in money market funds. Carrying values of cash equivalents approximate fair value due to the short-term nature of these instruments.
12

Table of Contents
Sema4 Holdings Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported on the condensed consolidated balance sheets that sum to the total of the same amounts shown on the condensed consolidated statements of cash flows (in thousands):
As of
March 31, 2022
As of
December 31, 2021
Cash and cash equivalents$315,002 $400,569 
Restricted cash900 900 
Total$315,902 $401,469 
Restricted cash as of March 31, 2022 consists of money market deposit accounts that secure an irrevocable standby letter of credit that serves as collateral for security deposit operating leases (see Note 9, “Leases”).
Warrant Liability
As of the consummation of the Prior Merger in July 2021, there were 21,995,000 warrants to purchase shares of Class A common stock outstanding, including 14,758,333 public warrants and 7,236,667 private placement warrants. As of December 31, 2021, there were 21,994,972 warrants to purchase shares of Class A common stock outstanding, including 14,758,305 public warrants and 7,236,667 private placement warrants outstanding. Each warrant expires five years after the Business Combination or earlier upon redemption or liquidation, and entitles the holder to purchase one share of Class A common stock at an exercise price of $11.50 per share, subject to adjustment, at any time commencing on September 4, 2021.
The Company may redeem the outstanding public warrants if the price per share of the Class A common stock equals or exceeds $18.00 as described below:

in whole and not in part;
at a price of $0.01 per public warrant;
upon not less than 30 days’ prior written notice of redemption to each warrant holder; and
if, and only if, the closing price of the Class A common stock equals or exceeds $18.00 per share (as adjusted) for any 20 trading days within a 30-trading day period ending three trading days before sending the notice of redemption to warrant holders.
The Company may redeem the outstanding public warrants if the price per share of the common stock equals or exceeds $10.00 as described below:

in whole and not in part;
at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares based on the redemption date and the fair market value of the common stock;
if, and only if, the closing price of the Class A common stock equals or exceeds $10.00 per share (as adjusted) for any 20 trading days within the 30-trading day period ending three trading days before the Company sends the notice of redemption to the warrant holders; and
if the closing price of the common stock for any 20 trading days within a 30-trading day period ending three trading days before the Company sends notice of redemption to the warrant holders is less than $18.00 per share (as adjusted), the private placement warrants must also be concurrently called for redemption on the same terms as the outstanding public warrants, as described above.
The private placement warrants were issued to CMLS Holdings, LLC, Mr. Munib Islam, Dr. Emily Leproust and Mr. Nat Turner, and are identical to the public warrants underlying the units sold in the initial public offering, except that (1) the private placement warrants and the common stock issuable upon the exercise of the private placement warrants would
13

Table of Contents
Sema4 Holdings Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
not be transferable, assignable or salable until 30 days after the completion of a Business Combination, subject to certain limited exceptions, (2) the private placement warrants are exercisable on a cashless basis, (3) the private placement warrants are non-redeemable (except as described above, upon a redemption of warrants when the price per share of Class A common stock equals or exceeds $10.00) so long as they are held by the initial purchasers or their permitted transferees, and (4) the holders of the private placement warrants and the common stock issuable upon the exercise of the private placement warrants have certain registration rights. If the private placement warrants are held by someone other than the initial purchasers or their permitted transferees, the private placement warrants will be redeemable by the Company and exercisable by such holders on the same basis as the public warrants.
The Company accounts for warrants as liability-classified instruments based on an assessment of the warrant terms and applicable authoritative guidance in accordance with ASC 480-Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815-Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, whether the warrants meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815. This assessment is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.
Earn-out contingent liability
In connection with the Prior Merger, all Legacy Sema4 stockholders and option holders at that time became entitled to a pro rata share of 19,021,576 earn-out shares and earn-out RSUs. Based on an assessment of the earn-out shares for the Legacy Sema4 stockholders, the Company considered ASC 480 and ASC 815 and accounted for the earn-out shares as a liability. The Company subsequently measures the fair value of the liability at each reporting period and reports the changes in fair value recorded as a component of other income (expense), net in the condensed consolidated statements of operations and comprehensive loss.
The Company determined the fair value of the earn-out shares issued to the Legacy Sema4 stockholders as of March 31, 2022 was $3.4 million.
As for the earn-out RSUs for the Legacy Sema4 option holders, a total of 2.7 million RSUs were granted on December 9, 2021. The vesting of such arrangement is conditioned on the satisfaction of both a service requirement and on the satisfaction of a market-based requirement. The market-based requirement would be achieved if the Company’s stock price is greater than or equal to $13 (Triggering Event I), $15 (Triggering Event II) and $18 (Triggering Event III) during the applicable performance period, based on the volume-weighted average price for a period of at least 20 days out of 30 consecutive trading days. Therefore, the Company accounts for this arrangement in accordance with ASC 718- Compensation — Stock Compensation (“ASC 718”) and stock-based compensation expense is recognized over the longer of the expected achievement period for the market-based requirement and the service requirement. The Company recorded $0.5 million of stock-based compensation expense in relation to the earn-out RSUs for the quarter ended March 31, 2022. In the event that any earn-out RSUs that are forfeited as a result of a failure to achieve the service requirement, the underlying shares will be reallocated on an annual basis to the Legacy Sema4 stockholders and to the Legacy Sema4 option holders who remain employed as of the date of such reallocation. The Company accounts for the re-allocations to Legacy Sema4 option holders as new grants.
The estimated fair value of the earn-out is determined using a Monte Carlo valuation analysis.
Capitalized Internal-Use Software Costs
The Company capitalizes certain costs incurred related to the development of its software applications for internal use during the application development state. If a project constitutes an enhancement to existing software, the Company assesses whether the enhancement creates additional functionality to the software, thus qualifying the work incurred for capitalization. Costs incurred prior to meeting these criteria together with costs incurred for training and maintenance are expensed as incurred. Once the project is available for general release, capitalization ceases and the Company estimates the useful life of the asset and begins amortization.
Restructuring Costs
During the three months ended March 31, 2022, the Company’s Compensation Committee of the Board of Directors approved by written consent dated February 17, 2022 a restructuring plan which was executed by management and
14

Table of Contents
Sema4 Holdings Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
$2.7 million of restructuring charges were incurred and recorded in connection therewith. These costs include severance packages offered to the employees impacted by the plan and third party consulting costs. Additionally, as discussed in the “Note 14—Subsequent Events”, the Board of Directors approved additional headcount reductions in an effort to streamline operations and the Company expects to recognize expenses of $5.4 million during the second quarter of 2022.
Emerging Growth Company
The Company is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012. As such, the Company is eligible for exemptions from various reporting requirements applicable to other public companies that are not emerging growth companies, including reduced reporting and extended transition periods to comply with new or revised accounting standards for public business entities. The Company has elected to avail itself of this exemption and, therefore, will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.
Recently Adopted Accounting Pronouncements in the First Quarter of 2022
In February 2016, the FASB issued ASU 2016-02, Leases (“Topic 842”), which requires lessees to recognize right-of-use assets and lease liabilities for most leases on their balance sheets. Expense recognition for lessees under ASC 842 is similar to current lease accounting. ASC 842 requires enhanced disclosures to help the financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The Company adopted ASC 842 as of January 1, 2022, utilizing the modified retrospective adoption approach. In transition to the ASC 842, the Company elected to use the package of practical expedients permitted under the transition guidance that allowed us to not reassess: (i) whether any expired or existing contracts are or contain leases, (ii) the lease classification for any expired or existing leases, or (iii) initial direct costs for any existing leases. Additionally, the Company did not elect the hindsight practical expedient which would have permitted the use of hindsight in determining the lease term and assessing impairment. The Company elected to combine lease and non-lease components that are fixed and also elected not to recognize right-of-use assets and lease liabilities for leases with terms of 12 months or less (“short-term leases”). The adoption of the ASC 842 as of January 1, 2022, resulted in the recognition of operating lease right-of-use assets and operating lease liabilities of $39.2 million and $42.2 million, respectively. The adoption did not have material impact on finance leases. The adoption did not have material impact on the condensed consolidated statements of operations and comprehensive loss. Refer to “Note 9 Leases” for a discussion of the Company’s lease accounting following the adoption of ASC 842.
In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832), Disclosures by Business Entities About Government Assistance, which requires entities to provide disclosures on material government assistance transactions for annual reporting periods. The disclosures include information around the nature of the assistance, the related accounting policies used to account for government assistance, the effect of government assistance on the entity’s financial statements, and any significant terms and conditions of the agreements, including commitments and contingencies. The Company adopted ASU 2021-10 effective January 1, 2022. The Company did not receive any such grants during the three months ended March 31, 2022.
Recently Issued Accounting Pronouncements Not Yet Adopted
In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). The new credit losses standard changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, contract assets recognized as a result of applying ASC 606, loans and certain other instruments, entities will be required to use a new forward looking “expected loss” model that generally will result in earlier recognition of credit losses than under today’s incurred loss model. As an emerging growth company, ASU 2016-13 is effective for annual periods beginning after December 15, 2022, with early adoption permitted. Application of the amendments is through a cumulative-effect adjustment to the opening retained earnings as of the beginning of the first reporting period in which the guidance is effective. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements and related disclosures.
15

Table of Contents
Sema4 Holdings Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
3. Business Combination
As discussed in Note 1, on July 22, 2021, the Company consummated the Business Combination and received net cash proceeds of $510.0 million.
Pursuant to the Business Combination, the following occurred:
Holders of 10,188 shares of CMLS’s Class A common stock sold in its initial public offering (the “public shares”) exercised their right to have such shares redeemed for a full pro rata portion of the trust account holding the proceeds from CMLS’s initial public offering (the “IPO”), which was approximately $10.00 per share, or $101,880 in aggregate.
Each share of CMLS’s Class B common stock was automatically converted into common stock of the Company.
Each share of the Legacy Sema4 Class B common stock was converted into 1/100th of a share of Legacy Sema4 Class A common stock and each share of Legacy Sema4 common stock and preferred stock was canceled and received a portion of the merger consideration, resulting in certain Legacy Sema4 stockholders receiving $230,665,220 of cash and the Legacy Sema4 stockholders receiving an aggregate of 178,336,298 shares of common stock of the Company.
Pursuant to subscription agreements entered into on February 9, 2021, certain investors agreed to subscribe for an aggregate of 35,000,000 newly-issued shares of common stock at a purchase price of $10.00 per share for an aggregate purchase price of $350,000,000 (the “PIPE Investment”). Concurrently with the closing of the Business Combination, the Company consummated the PIPE Investment.
After giving effect to the Prior Merger, the redemption of public shares and the conversion of the CMLS Class B common stock as described above, and the consummation of the PIPE Investment, there were 240,190,402 shares of the Company’s common stock issued and outstanding.
In 2021, the Company recorded $51.8 million of transaction costs which consisted of direct, incremental legal, professional, accounting, and other third-party fees that were directly related to the execution of the Prior Merger in additional paid-in capital. Upon consummation of the Prior Merger, $9.0 million of the transaction costs relates to costs incurred by Legacy Sema4 and reclassed to offset against equity from prepaid expense and other current assets.
4. Revenue Recognition
Diagnostic Revenue
The Company’s diagnostic test revenue contracts typically consist of a single performance obligation to deliver diagnostic testing services to the ordering facility or patient and therefore allocation of the contract transaction price is generally not applicable. Revenue from diagnostic testing services is recorded at the estimated transaction price, subject to the constraint for variable consideration, upon transfer of control of the service. Control over diagnostic testing services is generally transferred at a point in time when the customer obtains control of the promised service which is upon delivery of the test.
Other Revenue
The Company enters into both short-term and long-term project-based collaboration and service agreements with third parties, whereby the Company provides diagnostic testing, research and related data aggregation reporting services. The consideration to which the Company is entitled pursuant to its collaboration and service agreements includes non-refundable upfront payments, fixed and variable payments based upon the achievement of certain milestones during the contract term. Non-refundable upfront payments are generally received in advance of performing the services and, therefore, are recorded as a contract liability upon receipt. Fixed and variable milestone payments are included in the transaction price only when it is probable that doing so will not result in a significant reversal of cumulative revenue recognized when the uncertainty associated with the milestone is subsequently resolved. Revenue for such collaboration and service agreements is recognized over time using an input measure based on costs incurred to satisfy the performance obligation.
16

Table of Contents
Sema4 Holdings Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
Disaggregated revenue
The following table summarizes the Company’s disaggregated revenue by payor category (in thousands):

Three months ended March 31,
20222021
Diagnostic test revenue
Patients with third-party insurance
$47,462 $46,197 
Institutional customers
4,031 15,664 
Self-pay patients
1,002 899 
Total diagnostic test revenue
52,495 62,760 
Other revenue
1,446 1,441 
Total
$53,941 $64,201 
Reassessment of variable consideration
Subsequent changes to the estimate of the transaction price, determined on a portfolio basis when applicable, are generally recorded as adjustments to revenue in the period of the change. The Company updates estimated variable consideration quarterly.
For the three months ended March 31, 2022, the quarterly change in estimate resulted in a net $3.6 million increase to revenue for tests in which the performance obligation of delivering the test results was met in prior periods. The change in estimate is a result of changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met and settlements with third party payors. The quarterly change in estimate did not result in material adjustments to the Company’s previously reported revenue or accounts receivable amounts.
Remaining performance obligations
For certain long-term collaboration service agreements with original expected durations of more than one year, the Company’s obligations pursuant to such agreement represents partially unsatisfied performance obligations as of March 31, 2022. The revenues under the agreements are estimated to be approximately $10.3 million. The Company expects to recognize the majority of this revenue over the next 3 years.
Contract assets and liabilities
Contract assets consist of the Company’s right to consideration that is conditional upon its future performance. Contract assets arise in collaboration and service agreements for which revenue is recognized over time but the Company’s right to bill the customer is contingent upon the achievement of contractually-defined milestones.
Contract liabilities consist of customer payments in excess of revenues recognized. For collaboration and service agreements, the Company assesses the performance obligations and recognizes contract liabilities as current or non-current based upon forecasted performance.
17

Table of Contents
Sema4 Holdings Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
A reconciliation of the beginning and ending balances of contract assets and contract liabilities is shown in the table below (in thousands):
Contract
Assets
Contract
Liabilities
December 31, 2021
$3,296 $3,769 
Contract asset additions
453 — 
Customer prepayments
— 350 
Revenue recognized
— (304)
March 31, 2022
$3,749 $3,815 
The Company presents contract assets and contract liabilities with respect to customer contracts on a net basis on its condensed consolidated balance sheets. As of March 31, 2022 and December 31, 2021, $0.1 million and $0.5 million is recorded as current contract liabilities, respectively.
Revenues recognized for the three months ended March 31, 2022 and March 31, 2021 that were included in the contract liability balance at the beginning of each period were $0.5 million and $0.5 million, respectively.
Costs to fulfill contracts
Costs associated with fulfilling the Company’s performance obligations pursuant to its collaboration service agreements include costs for services that are subcontracted to ISMMS. Amounts prepaid are expensed in line with the pattern of revenue recognition. Prepayment of amounts prior to the costs being incurred are recognized on the condensed consolidated balance sheets as current or non-current based upon forecasted performance.
As of March 31, 2022 and December 31, 2021, the Company had outstanding deferred costs to fulfill contracts of $1.5 million and $1.8 million, respectively. As of March 31, 2022 and December 31, 2021, all outstanding deferred costs were recorded as other current assets.
Amortization of deferred costs was $0.3 million and $0.3 million for the three months ended March 31, 2022 and 2021, respectively. The amortization of these costs is recorded in the cost of services on the condensed consolidated statements of operations and comprehensive loss.
5. Fair Value Measurements

Financial assets and liabilities are recorded at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines the fair value of its financial instruments based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. The following hierarchy lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market:

Level 1: Observable inputs such as quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities.

Level 2: Observable inputs such as quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active or model-derived valuations whose significant inputs are observable.
Level 3: Unobservable inputs that are significant to the measurement of fair value but are supported by little to no market data.
The Company’s financial assets and liabilities consist of cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued liabilities, finance leases, warrant liability, earn-out contingent liability and long-
18

Table of Contents
Sema4 Holdings Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
term debt. The Company’s cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to the relatively short-term nature of these accounts.
The Company’s finance leases are classified within Level 1 of the fair value hierarchy because such finance lease agreements bear interest at rates for instruments with similar characteristics; accordingly, the carrying value of these liabilities approximate their fair values.
The Company’s loan from the Connecticut Department of Economic and Community Development is classified within Level 2 of the fair value hierarchy. As of March 31, 2022, the long-term debt was recorded at its carrying value of $11.0 million in the condensed consolidated balance sheet. The fair value was $9.5 million, which is estimated based on discounted cash flows using the yields of similar debt instruments of other companies with similar credit profiles.
The following tables set forth the fair value of financial instruments that were measured at fair value on a recurring basis (in thousands):
As of March 31, 2022
TotalLevel 1Level 2Level 3
Financial Assets:
Money market funds
$62,282 $62,282 $ $ 
Total financial assets
$62,282 $62,282 $ $ 
Financial Liabilities:
Public warrant liability
$10,183 $10,183 $ $ 
Private warrant liability
4,993  4,993  
Earn-out contingent liability3,432   3,432 
Total financial liabilities
$18,608 $10,183 $4,993 $3,432 
As of December 31, 2021
TotalLevel 1Level 2Level 3
Financial Assets:
Money market funds
$385,370 $385,370 $ $ 
Total financial assets
$385,370 $385,370 $ $ 
Financial Liabilities:
Public warrant liability
$14,463 $14,463 $ $ 
Private warrant liability
7,092  7,092  
Earn-out contingent liability10,244   10,244 
Total financial liabilities
$31,799 $14,463 $7,092 $10,244 

Of the $315.0 million cash and cash equivalents presented on the condensed consolidated balance sheets as of March 31, 2022, $62.3 million was in money market funds and was classified within Level 1 of the fair value hierarchy as the fair value was based on quoted prices in active markets.
The Company’s outstanding warrants include publicly-traded warrants (the “Public Warrants”) which were originally issued in the IPO and warrants sold in a private placement to CMLS Holdings LLC (the “Private Warrants”). The Company evaluated its warrants under ASC 815-40, Derivatives and Hedging—Contracts in Entity’s Own Equity, and concluded that they do not meet the criteria to be classified in stockholders’ equity. Since the Public Warrants and Private Warrants meet the definition of a derivative under ASC 815, the Company recorded these warrants as non-current liabilities on the balance sheet at fair value upon the closing of the Business Combination, with subsequent changes in their respective fair values recognized in other income (expense), net on the condensed consolidated statements of operations and comprehensive loss at each reporting date. As of March 31, 2022, the Public Warrants are classified within Level 1 of the fair value hierarchy as they are traded in active markets. The Private Warrants are classified within Level 2 of the fair
19

Table of Contents
Sema4 Holdings Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
value hierarchy as management determined the fair value of each Private Warrant is the same as that of a Public Warrant because the terms are substantially the same.

The contingent obligation to issue earn-out shares for Legacy Sema4 stockholders was accounted for as a liability and required remeasurement at each reporting date. The estimated fair value of the total earn-out shares as of March 31, 2022 is determined based on a Monte Carlo simulation valuation model. The fair value of the earn-out contingent liability is sensitive to expected volatility estimated based on selected guideline public companies’ stock prices, the Company’s implied volatility and Company’s common stock price which is sensitive to changes in the forecasts of earnings and/or the relevant operating metrics. The key assumptions utilized in determining the valuation as of March 31, 2022 and December 31, 2021 were as follows:

March 31, 2022December 31, 2021
Stock price$3.07$4.46
Expected volatility72.5%62.5%
Expected term (in years)1.31.6
Risk-free interest rate1.83%0.58%
The earn-out contingent liability is categorized as Level 3 of the fair value hierarchy as the Company utilizes unobservable inputs in estimating volatility rate. The fair value determined and recorded as of December 31, 2021 was $10.2 million and during the three months ended March 31, 2022 a gain of $6.8 million was recorded in the change in fair market value of warrant and earn-out contingent liability in the condensed consolidated statements of operations and comprehensive loss based on re-measurement performed as of the period end date.
There were no transfers between Level 1, Level 2 and Level 3 during the periods presented.
6. Property and Equipment
Property and equipment, net consisted of the following (in thousands):
As of
March 31,
2022
As of
December 31,
2021
Laboratory equipment$27,838 $28,552 
Equipment under finance leases
21,384 21,384 
Leasehold improvements
21,915 21,905 
Capitalized software
27,797 25,693 
Building under finance lease
6,276 6,276 
Construction in-progress
2,709 940 
Computer equipment
7,536 6,634 
Furniture, fixtures and other equipment
3,230 3,241 
Total property and equipment
118,685 114,625 
Less: accumulated depreciation and amortization
(57,709)(51,906)
Property and equipment, net
$60,976 $62,719 
For the three months ended March 31, 2022 and 2021, depreciation and amortization expense was $5.8 million and $4.9 million. This included software amortization expense of $1.6 million and $1.2 million for the three months ended
20

Table of Contents
Sema4 Holdings Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
March 31, 2022 and 2021. Depreciation and amortization expense is included within the condensed consolidated statements of operations and comprehensive loss as follows (in thousands):
Three months ended March 31,
20222021
Cost of services$2,816 $3,058 
Research and development
1,849 1,251 
Selling and marketing
1  
General and administrative
1,137 593 
Total depreciation and amortization expenses
$5,803 $4,902 
7. Related Party Transactions
For three months ended March 31, 2022 and 2021, the Company incurred certain related party costs. There were no expenses recognized under the TSA for the three months ended March 31, 2022 and $1.4 million for the three months ended March 31, 2021 which is presented within related party expenses in the condensed consolidated statements of operations and comprehensive loss. The Company had no TSA payables due to ISMMS as of March 31, 2022 and December 31, 2021.
Expenses recognized pursuant to other service arrangements with ISMMS, including certain sub-lease arrangements the Company has through ISMMS, totaled $1.9 million and $0.7 million for the three months ended March 31, 2022 and 2021, respectively. These amounts include certain lease expenses the Company incurs and pay to ISMMS for certain sub-lease arrangements. They are included in either cost of services or related party expenses on the condensed consolidated statements of operations and comprehensive loss depending on the particular activity to which the costs relate. Payables due to ISMMS for the other service arrangements were $2.5 million $2.6 million as of March 31, 2022 and December 31, 2021, respectively. These amounts include unpaid lease payments the Company accrued for the payments to be made to ISMMS and are included within due to related parties on the Company’s condensed consolidated balance sheets.
Additionally, since the closing of the Prior Merger in July 2021 the Company has purchased $0.7 million of diagnostic testing kits and materials of which $0.4 million was recorded in cost of services for the three months ended March 31, 2022 from an affiliate of a member of the Board of Directors who has served in the role since July 2021. The prices paid represent market rates. Payables due were $0.7 million and $0.1 million as of March 31, 2022 and December 31, 2021, respectively.
Total related party costs are included within cost of services and related party expenses in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands):
Three months ended March 31,
20222021
Cost of services$1,056 $278 
Related party expenses
1,284 1,797 
Total related party costs
$2,340 $2,075 

8. Long-Term Debt
Loan and Security Agreement (the “SVB Agreement”)

On November 15, 2021, the Company and Sema4 OpCo, Inc. (together, the “Borrower”) entered into a Loan and Security Agreement (the “SVB Agreement”) with Silicon Valley Bank (“SVB”). The SVB Agreement provides for a revolving credit facility (the “Revolver”) up to an aggregate principal amount of $125.0 million, including a sublimit of $20.0 million for Letters of Credit (as such terms are defined in the SVB Agreement). The outstanding principal amount of any Advance (as such term is defined in the SVB Agreement) will bear interest at a floating rate per annum equal to the greater of (1) 4.00% and (2) the Prime Rate plus the Prime Rate Margin. The Revolver will mature on November 15, 2024. In connection with entering into the SVB agreement, the Company paid $0.5 million in debt issuance costs during 2021.
21

Table of Contents
Sema4 Holdings Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
The Company will pay an additional $0.5 million in fees to SVB at each anniversary of the SVB Agreement date for a total of $1.0 million and these fees are recorded in other current liabilities and other liabilities in the condensed consolidated balance sheets as of March 31, 2022. These costs are capitalized and amortized on a straight-line basis over the contractual term. Any unused fees charged on the Revolver is expensed as incurred.

The obligations under the SVB Agreement are secured by a first priority perfected security interest in substantially all of the Borrower’s assets except for (i) Governmental Collection Accounts (as defined in the SVB Agreement), (ii) more than 65% of the presently existing and thereafter arising issued and outstanding shares of capital stock owned by Borrowers in a Foreign Subsidiary (as such term is defined in the SVB Agreement) and (iii) intellectual property pursuant to the terms of the SVB Agreement.

The SVB Agreement contains affirmative and negative covenants, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, and dividends and other distributions.
The SVB Agreement requires the Borrower to comply with certain financial covenants if Liquidity (as such term is defined in the SVB Agreement) falls below $135.0 million. These financial covenants include (i) a minimum Adjusted Quick Ratio (as such term is defined in the SVB Agreement) and (ii) the achievement of certain minimum revenue targets. On a monthly basis, the Borrowers would be required to maintain a minimum Adjusted Quick Ratio of greater than or equal to 1.25 to 1.0. The Borrower must also maintain certain trailing six-month minimum revenue targets through maturity if outstanding borrowings under the Revolver exceed $50.0 million.

The SVB Agreement also includes customary events of default, including failure to pay principal, interest or certain other amounts when due, material inaccuracy of representations and warranties, violation of covenants, certain bankruptcy and insolvency events, certain undischarged judgments, material invalidity of guarantees or grant of security interest, material adverse change, and involuntary delisting from the Nasdaq Stock Market, in certain cases subject to certain thresholds and grace periods. If one or more events of default occurs and continues beyond any applicable cure period, SVB may, without notice or demand to the Borrower, terminate its commitment to make further loans and declare all of the obligations of the Borrowers under the SVB Agreement to be immediately due and payable. The Company was in compliance with all covenants as of March 31, 2022.
No amounts have been drawn under the SVB Agreement as of March 31, 2022.
2016 Funding Commitment
In June 2017, ISMMS assigned a loan funding commitment from the Connecticut Department of Economic and Community Development (“DECD”) to the Company (as amended, the “DECD Loan Agreement”). The DECD Loan Agreement, provides for a total loan commitment of $15.5 million at a fixed annual interest rate of 2.0% for a term of 10 years. The Company is required to make interest-only payments through July 2023 and principal and interest payments commencing in August 2023. The final payment of principal and interest is due in July 2028. However, under the terms of the DECD Loan Agreement, the DECD may grant partial principal loan forgiveness of up to $12.3 million in the aggregate. Such forgiveness is contingent upon the Company achieving job creation and retention milestones and $7.3 million has been forgiven as of March 31, 2022. This commitment is collateralized by providing a security interest in certain machinery and equipment the Company acquired from ISMMS, as defined in a separate security agreement.
The outstanding loan balance from the DECD Loan Agreement was $11.0 million as of March 31, 2022 and December 31, 2021.
22

Table of Contents
Sema4 Holdings Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
Maturities of Long-Term Debt
As of March 31, 2022, long-term debt matures as follows (in thousands):
2022 (remainder of year)
$ 
2023875 
20242,131 
20252,174 
20262,218 
Thereafter3,602 
Total maturities of long-term debt
11,000 
Less: current portion of long-term debt
 
Total long-term debt, net of current maturities
$11,000 
2020 Master Loan Agreement
In August 2020, the Company entered into a loan and security agreement with a bank (the “Master Loan Agreement”), in which the Company received a loan of $6.3 million and deposited the proceeds into a deposit account held by the bank. The Company was required to make sixty consecutive monthly payments of principal and interest at a fixed monthly amount of $0.1 million beginning in November 2020. Interest payments were fixed at an annual interest rate of 4.75%.
In July 2021, the Company terminated the Master Loan Agreement by paying off the full amount, including $5.4 million principal and interest and $0.1 million in early payment penalties assessed pursuant to the terms of the agreement.
2020 Master Lease Agreement
In December 2020, the Company entered into a lease agreement with a lender whereby the Company agreed to sell certain equipment and immediately lease back the equipment, resulting in proceeds of $3.6 million. Per the terms of the agreement, a financial institution issued an irrevocable standby letter of credit to the lender for $3.6 million. The Company was required to make sixty consecutive monthly payments of principal and interest at a fixed monthly amount of $0.1 million beginning in February 2021. Interest payments were fixed at an annual interest rate of 3.54%.
The Company was required to maintain an aggregate amount on deposit equal to at least 105% of the value of any outstanding letters of credit issued by the financial institution on the Company’s behalf. The letter of credit was required to be in place until all obligations had been paid in full. Further, the Company was required to furnish annual audited financial statements and other financial information to the lender on a regular basis.
In July 2021, the Company terminated the Master Lease Agreement by paying off the full amount, including $3.3 million principal and interest and early payment penalties of $0.2 million assessed pursuant to the terms of the agreement.
9. Leases
Lease Accounting

The Company enters into contracts in the normal course of business and assesses whether any such contracts contain a lease. The Company determines if an arrangement is a lease at inception if it conveys the right to control the identified asset for a period of time in exchange for consideration. The Company classifies leases as operating or financing in nature. All lease liabilities are measured at the present value of the associated payments, discounted using the Company’s incremental borrowing rate determined based on the rate of interest that the Company would pay to borrow on a
23

Table of Contents
Sema4 Holdings Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
collateralized basis an amount equal to the lease payments for similar term and in a similar economic environment on a collateralized basis, unless there is a rate implicit in the lease that is readily determinable.
Operating Leases
The Company's operating lease arrangements are principally for office space and laboratory facilities. The Company’s headquarter lease was initially entered into via sub-lease agreements with ISMMS and a third party and they will expire in 2034. The agreements include escalating rent and rent-free period provisions. Pursuant to the terms of the lease agreement, the Company was required to have issued an irrevocable standby letter of credit to the lessor for $0.9 million, which was included in restricted cash on the condensed consolidated balance sheets as of March 31, 2022 and consolidated balance sheets as of December 31, 2021.
In April 2019, the Company entered into a sublease agreement to rent a building to be used for office and laboratory facility (the “Stamford Lease”) for a base term of 325 months, expiring in October 2046. The Company has the option to renew the lease at the end of the initial base term for either one period of 10 years, or two periods of 5 years. There is also an early termination option in which the Company may cancel the lease after the 196th month with cancellation fees. At inception of the Stamford Lease, the value of the land was determined to be more than 25% of the total value and therefore the building is accounted for as a finance lease and the land as an operating lease.
In January 2020, the Company entered into a lease agreement which expanded the Company’s existing laboratory facility in Branford, Connecticut. The lease commenced in February 2020 with a 10 year term. The lease includes escalating rent fees over the lease term.
Finance Leases
The Company enters into various finance lease agreements to obtain laboratory equipment that contain bargain purchase commitments at the end of the lease term. The leases are secured by the underlying equipment. As discussed above, the Company also leases a building used for office and laboratory space in which the building is accounted for as a finance lease and the land is as an operating lease. The interest rate used for the Stamford Lease is 13.1%, which is used to measure the operating and finance lease liability.
The tables below present financial information associated with the Company’s leases. This information is only presented as of, and for the three months ended, March 31, 2022 because, the Company adopted the ASC 842 using a transition method that does not require application to periods prior to adoption (in thousands).
ClassificationMarch 31, 2022
Assets
Operating lease assetsOperating lease right-of-use assets$38,417 
Finance lease assetsProperty and Equipment, net13,190 
Total lease assets$51,607 
Liabilities
Current
OperatingDue to related parties$566 
Short-term lease liabilities1,892 
FinanceDue to related parties304 
Short-term lease liabilities3,180 
Non-current
OperatingLong-term lease liabilities39,649 
FinanceLong-term lease liabilities17,829 
Total lease liabilities$63,420 
24

Table of Contents
Sema4 Holdings Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
Lease costThree months ended March 31, 2022
Operating lease cost
Operating lease cost$1,380 
Short-term lease cost169 
Variable lease cost127 
Total operating lease cost$1,676 
Finance lease cost
Depreciation and amortization of leased assets$912 
Interest on lease liabilities552 
Total finance lease cost$1,464 
Total lease cost$3,140 

Future minimum lease payments under non-cancellable leases as of March 31, 2022 are as follows:
Maturity of lease liabilitiesOperating leasesFinance leasesTotal
2022 (remainder of the year)$3,862 $3,808 $7,670 
20234,338 3,584 7,922 
20244,440 2,763 7,203 
20254,835 2,451 7,286 
20264,949 2,003 6,952 
Thereafter51,920 49,884 101,804 
Total$74,344 $64,493 $138,837 
Less: imputed interest$(32,237)$(43,180)$(75,417)
Present value of lease liabilities$42,107 $21,313 $63,420 
Other information related to leases as of and the three months ended March 31, 2022 are as follows:
March 31, 2022
Weighted-average remaining lease term (years)
Operating leases13.5
Finance leases17.8
Weighted-average discount rate
Operating leases6.8%
Finance leases10.5%
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases$1,236
Operating cash flows from finance leases$552
Financing cash flows from finance lease$862
25

Table of Contents
Sema4 Holdings Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
10. Commitments and Contingencies
Purchase Obligations
In the normal course of business, the Company enters into various purchase commitments primarily related to material and service agreements, laboratory supplies and software. At March 31, 2022, the Company’s total future payments under noncancelable unconditional purchase commitments having a remaining term of over one year were $19.4 million.
Contingencies
The Company is a party to various actions and claims arising in the normal course of business. The Company does not believe that the outcome of these matters will have a material effect on the Company’s condensed consolidated financial position, results of operations or cash flows. However, no assurance can be given that the final outcome of such proceedings will not materially impact the Company’s condensed consolidated financial condition or results of operations.
The Company was not a party to any material legal proceedings as of March 31, 2022, nor is it a party to any material legal proceedings as of the date of issuance of these unaudited condensed consolidated financial statements.
11. Stock-Based Compensation
Stock Incentive Plans
The Company’s 2017 Equity Incentive Plan (the “2017 Plan”), as amended in February 2018, allowed the grant of options, restricted stock awards, stock appreciation rights and restricted stock units. No options granted under the 2017 Plan are exercisable after 10 years from the date of grant, and option awards generally vest over a four-year period.
The 2017 Plan was terminated in connection with the adoption of the Company's 2021 Equity Incentive Plan (the "2021 Plan"). Any awards granted under the 2017 Plan that remained outstanding as of the Closing Date and were converted into awards with respect to the Company’s Class A common stock in connection with the consummation of the Business Combination continue to be subject to the terms of the 2017 Plan and applicable award agreements, except for a modification of the repurchase provision, which is discussed further below.
On July 22, 2021, in connection with the Business Combination, the 2021 Plan became effective and 32,734,983 authorized shares of Class A common stock were reserved for issuance thereunder. This Plan will be administered by the Compensation Committee of the Company’s Board of Directors, including determination of the vesting, exercisability and payment of the awards to be granted under this Plan. No awards granted under the 2021 Plan are exercisable after 10 years from the date of grant, and the awards granted under the 2021 Plan generally vest over a four-year period on a graded vesting basis.
Employee Stock Purchase Plan
The 2021 Employee Stock Purchase Plan (the “2021 ESPP”) became effective in connection with the Business Combination. The 2021 ESPP authorizes the issuance of shares of Class A common stock pursuant to purchase rights granted to employees. On each January 1 of each of 2022 through 2031, the aggregate number of shares of Class A common stock reserved for issuance under the 2021 Plan may be increased automatically by the number of shares equal to one percent (1%) of the total number of shares of all classes of common stock issued and outstanding immediately preceding December 31. The Company did not make any grants of purchase rights under the 2021 ESPP during the quarter ended March 31, 2022. A total of 7,229,799 shares of Class A common stock have been reserved for future issuance under the 2021 ESPP.
Stock Option Activity
Under the 2017 Plan, the Company had a call option to repurchase awards for cash from the plan participants upon termination of the participant’s employment or consulting agreement (the “2017 Plan Call Option”). The options granted under the 2017 plan were accounted for as liability awards due to the 2017 Plan Call Option. The Company had a history of repurchase practice and the intention to repurchase the vested options. Therefore, the fair value of the liability awards was remeasured at each reporting period until the stockholder bears the risks and rewards of equity ownership for a reasonable period of time, which the Company concludes is at least six months.
26

Table of Contents
Sema4 Holdings Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
Upon consummation of the Business Combination, the Company’s Board of Directors waived the Company’s right under the 2017 Plan Call Option to repurchase awards for cash from the plan participants upon termination of the participant’s employment or consulting agreement. As such, the Company modified the liability awards to equity awards and reclassified the modification date fair value of the awards to stockholders’ equity in the condensed consolidated financial statements as of July 22, 2021.
All stock options granted under the 2021 Plan are accounted for as equity awards.
The following summarizes the stock option activity, which reflects the conversion of the options granted under the 2017 Plan into awards with respect to the Company Class A common stock in connection with the consummation of the Business Combination (in thousands, except share and per share amounts):

Stock Options Outstanding
Weighted Average Exercise Price
Balance at December 31, 202130,905,543$1.24 
Options granted851,884$3.37 
Options exercised(2,108,502)$